Clinical trial NCT01149746: Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions
Official title: A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Teva Pharmaceuticals USA
Sponsor class: INDUSTRY
First posted: 2010-06-23
Enrollment: 32
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The objective of this study is to evaluate the comparative bioavailability between Tamsulosin Hydrochloride 0.4 mg Capsules (Teva Pharmaceuticals USA) and Flomax® 0.4 mg Capsules (Boehringer Ingelheim Pharmaceuticals, Inc. USA), after a single-dose in healthy subjects under fasting conditions.


Eligibility criteria: Inclusion Criteria:

* Healthy, non-smoking male subjects, 18 years of age or older.
* BMI greater than or equal to 19 and less than or equal to 30.
* Negative for:

  * HIV.
  * Hepatitis B surface antigen and Hepatitis C antibody.
  * Using drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
  * Urine cotinine test
* No significant diseases or clinically significant findings in a physical examination.
* No clinically significant abnormal laboratory values.
* No clinically significant findings in vital signs measurements and a 12-lead electrocardiogram (ECG).
* Systolic blood pressure between 100-140 mmHg and diastolic blood pressure between 60-90 mmgHg.
* Be informed of the nature of the study and given written consent prior to receiving any study procedure.

Exclusion Criteria:

* Known history or presence of any clinically significant medical condition, illness or surgery within 4 weeks prior to drug administration.
* Known or suspected carcinoma.
* Known history or presence of:

  * Hypersensitivity or idiosyncratic reaction to tamsulosin and/or any other drug substances with similar activity.
  * Alcoholism within the last 12 months.
  * Drug dependence and/or substance abuse.
  * Use of tobacco or nicotine-containing products within the last 6 months.
* Use of any prescription medication within 14 days prior to Period 1 dosing. Use of any over the counter (OTC) medication within 7 days prior to Period 1 dosing.
* Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to Period 1 dosing.
* On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein, raw food diet).
* Participated in another clinical trial or received and investigational product within 30 days prior to drug administration.
* Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 500 mL of blood in the previous 45 days OR Donated more than 500 mL of blood in the previous 56 days (based on the Canadian Blood Services guideline for blood donation.
* Difficulty fasting or consuming the standard meals.
* Do not tolerate venipuncture.
* Unable to read or sign the ICF.

Primary outcomes:
measure: Cmax (maximum observed concentration of drug substance in plasma)
timeFrame: Blood samples drawn over 60 hour time period
measure: AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration)
timeFrame: Blood samples drawn over 60 hour time period
measure: AUC0-inf (area under the concentration-time curve from time zero to infinity)
timeFrame: Blood samples drawn over 60 hour time period
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Pharma Medica Research Inc.
state: Ontario
Study officials:
affiliation: Pharma Medica Research, Inc.
name: Xueyu (Eric) Chen, M.D., Ph. D., FRCP (C)
role: PRINCIPAL_INVESTIGATOR
References: